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Abstract
Polycomb repressive complex 2 (PRC2) trimethylates lysine 27 of histone H3 (H3K27me3) to regulate gene expression
during diverse biological transitions in development, embryonic stem cell (ESC) differentiation, and cancer. Here, we show
that Polycomb-like 3 (Pcl3) is a component of PRC2 that promotes ESC self-renewal. Using mass spectrometry, we identified
Pcl3 as a Suz12 binding partner and confirmed Pcl3 interactions with core PRC2 components by co-immunoprecipitation.
Knockdown of Pcl3 in ESCs increases spontaneous differentiation, yet does not affect early differentiation decisions as
assessed in teratomas and embryoid bodies, indicating that Pcl3 has a specific role in regulating ESC self-renewal. Consistent
with Pcl3 promoting PRC2 function, decreasing Pcl3 levels reduces H3K27me3 levels while overexpressing Pcl3 increases
H3K27me3 levels. Furthermore, chromatin immunoprecipitation and sequencing (ChIP-seq) reveal that Pcl3 co-localizes
with PRC2 core component, Suz12, and depletion of Pcl3 decreases Suz12 binding at over 60% of PRC2 targets. Mutation of
conserved residues within the Pcl3 Tudor domain, a domain implicated in recognizing methylated histones, compromises
H3K27me3 formation, suggesting that the Tudor domain of Pcl3 is essential for function. We also show that Pcl3 and its
paralog, Pcl2, exist in different PRC2 complexes but bind many of the same PRC2 targets, particularly CpG islands regulated
by Pcl3. Thus, Pcl3 is a component of PRC2 critical for ESC self-renewal, histone methylation, and recruitment of PRC2 to a
subset of its genomic sites.
Citation: Hunkapiller J, Shen Y, Diaz A, Cagney G, McCleary D, et al. (2012) Polycomb-Like 3 Promotes Polycomb Repressive Complex 2 Binding to CpG Islands
and Embryonic Stem Cell Self-Renewal. PLoS Genet 8(3): e1002576. doi:10.1371/journal.pgen.1002576
Editor: Giacomo Cavalli, Centre National de la Recherche Scientifique, France
Received August 29, 2011; Accepted January 18, 2012; Published March 15, 2012
Copyright:  2012 Hunkapiller et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research was made possible by a grant from the California Institute for Regenerative Medicine (Grant Number TG2-01153). The contents of this
publication are solely the responsibility of the authors and do not necessarily represent the official views of CIRM or any other agency of the State of California.
This work was also funded by grants from the National Institutes of Health (RO1AR054396), the Burroughs Wellcome Fund, the Packard Foundation, the Sandler
Family Supporting Foundation, and the Helmsley Charitable Trust to JFR and also by fellowships from Genentech and the California Institute for Regenerative
Medicine to JH. AD and JSS were partially supported by grants from the PhRMA Foundation and UCSF RAP and Academic Senate. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: songj@humgen.ucsf.edu (JSS); Jeremy.Reiter@ucsf.edu (JFR)
Introduction
The developmental plasticity of early embryos and embryonic
stem cells (ESCs) requires the repression of cell-type specific genes.
Two multiprotein complexes that participate in gene repression
are Polycomb repressive complex 1 (PRC1) and Polycomb
repressive complex 2 (PRC2) [1,2]. Core components of PRC2
include Suz12, Eed, and Ezh2, a methyltransferase that partici-
pates in di- and tri-methylation of lysine 27 on histone H3
(H3K27me2/3) [2–7]. Trimethylation of H3K27 can modulate
the function of PRC1, which mono-ubiquitinates histone H2A on
lysine 119 (H2AK119Ub) [3,4]. Both H3K27me3 and
H2AK119Ub are early histone modifications involved in gene
repression [7].
Whereas H3K27me3 is associated with repressed genes,
H3K4me3 marks active genes. ESCs and a number of adult stem
cells, however, contain a unique chromatin signature, termed
bivalency, that is comprised of both H3K27me3 and H3K4me3
marks [8–15]. Many bivalent domains are at CpG islands,
domains of DNA with elevated GC content that display low
levels of DNA methylation. CpG islands are commonly found at
vertebrate promoters and are associated with 70% of annotated
genes including most housekeeping genes and many developmen-
tally regulated genes [16–18]. CpG-rich domains commonly
display H3K4me3, but GC-rich sequences also promote
H3K27me3, creating opposing marks within the same domain
[19,20]. By occupying CpG islands and marking them as bivalent
domains in ESCs, PRC2 may keep the associated genes repressed
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PRC2 is recruited to CpG islands is not known.
Disrupting core components of PRC2 causes a global reduction
of H3K27me3 and misexpression of repressed genes, particularly
bivalent genes [11,21–24]. This dysregulation of gene expression
perturbs ESC maintenance and differentiation, and results in
embryonic lethality in mice [23,25–30]. Furthermore, expression
of PRC1 and PRC2 components is misregulated in diverse
cancers, suggesting that PRC2-dependent gene regulation protects
against neoplasia [31–34].
Beyond the core components of PRC2, accessory proteins such
as Aebp2, Rbbp4/7, and Jarid2, influence PRC2 function [3,35–
40]. Recently, Polycomb-like (Pcl) proteins, named for the
similarity of the Drosophila Pcl mutant phenotype to that of the
Polycomb mutant, have been found to modulate PRC2 activity [41–
48]. Drosophila Pcl has three homologs in mammals: Pcl1 (also
called PHD finger protein 1), Pcl2 (also called Metal response
element binding transcription factor 2), and Pcl3 (also called PHD
finger protein 19) [49]. Pcl1 is expressed minimally in ESCs, but
promotes PRC2 function in adult tissues and male germ cells
[41,50–52]. Pcl2 regulates PRC2 differentially depending on cell
context and target. In mouse embryonic fibroblasts (MEFS), Pcl2
inhibits PRC2 activity, whereas in ESCs, Pcl2 hinders H3K27me3
formation globally but promotes PRC2 activity at a subset of genes
[41,47,48]. Human Pcl3 exists as two isoforms, which can bind
Ezh2 and Eed [53]. Mammalian Pcl3 is expressed in ESCs, but it
has been unclear how it contributes to PRC2 function and ESC
biology.
Here, we show that mouse Pcl3 interacts with the core
components of PRC2 and promotes complex function. By
depleting Pcl3 in ESCs, we demonstrate that Pcl3 contributes to
ESC self-renewal, but not differentiation, of the three germ layers.
Using ChIP-seq of Pcl3 shRNA-treated cells, we show that Pcl3
knockdown causes decreased H3K27me3 and Suz12 binding to
the genome, indicating that Pcl3 regulates PRC2 binding at
diverse target genes. Furthermore, Pcl3 localizes with Suz12 at a
subset of PRC2 targets, including genes and microRNAs
associated with differentiation and development. We also show
that several Pcl3 Tudor domain residues are necessary for
H3K27me3. Finally, we identify two GC-rich binding motifs that
are enriched at Pcl3-dependent PRC2 targets, indicating that Pcl3
promotes PRC2 binding at CpG islands. Taken together, these
results reveal that Pcl3 is an important regulator of PRC2 at a
subset of target genes.
Results
Pcl3 is a component of PRC2
To identify PRC2 binding partners that could contribute to its
function, we used the recently developed Floxin system to create a
tandem affinity purification (TAP) tagged allele of Suz12 (Figure
S1A) [54]. In brief, we reverted a Suz12 gene trap (Suz12
Gt/+) allele
generated in a mouse ESC line to produce an allele that re-
expresses Suz12 but that contains a loxP targeting site (Suz12
Rev/+).
Via a modified Floxin shuttle vector, we inserted an exon encoding
amino acids 277–741 of Suz12 fused to a carboxy-terminal 66His-
36Flag TAP tag. The resultant allele (Suz12
Suz12TAP/+) expressed
the full-length TAP-tagged Suz12 from the endogenous locus
(Figure 1A and Figure S1B). We measured protein and mRNA
levels of Suz12 in all ESC lines by immunoblot and quantitative
reverse transcription PCR (qRT-PCR) (Figure 1A and Figure
S1C). As expected, Suz12
Gt/+ cells displayed reduced Suz12
expression, whereas Suz12
Rev/+ cells displayed levels restored to
wild type amounts (Figure 1A and Figure S1C). Suz12
Suz12TAP/+
cells displayed moderately increased mRNA and protein levels of
Suz12 compared to wild type (Figure 1A and Figure S1C).
To reveal novel binding partners of Suz12, we tandem affinity
purified Suz12-TAP from Suz12
Suz12TAP/+ ESCs and identified co-
purified proteins by mass spectrometry (Figure 1B) [41]. The
PRC2 core components Eed, Ezh1, and Ezh2 were highly
represented among Suz12 co-purified proteins, as were other
known PRC2 interactors, including Rbbp4, Rbbp7, Aebp2,
Jarid2, Pcl2, and esPRC2p48 [3,35–41,47,48]. In addition, we
identified Pcl3 as co-purifying with Suz12. Human Pcl3 contains a
long and short isoform, both of which are associated with PRC2 in
HEK 293 cells by gel filtration chromatography [53]. To verify
binding of mouse Pcl3 with PRC2, we confirmed that V5-tagged
Pcl3 co-immunoprecipitated with Suz12-TAP in ESCs (Figure 1C
and Figure S1D). To determine whether Pcl3 interacts with all
PRC2 core members, we immunoprecipitated Pcl3-V5 and
probed for Suz12, Ezh2, and Eed. All core components of
PRC2 were found to bind Pcl3 (Figure 1D). Thus, mass
spectrometric and co-immunoprecipitation analyses indicated that
Pcl3 interacts with PRC2.
Pcl3 promotes ESC self-renewal
Inhibiting PRC2 activity can affect both ESC self-renewal and
differentiation by deregulating cell-type specific genes [22,24–
27,29,30]. Suz12
2/2 ESCs cannot form neural lineages, whereas
Eed
2/2 ESCs show an increased propensity to differentiate
[23,24,29,55]. To determine if Pcl3 regulates ESC maintenance
or differentiation, we tested whether Pcl3 knockdown altered the
ability of ESCs to self-renew or generate cell types derived from all
three germ layers.
We depleted Pcl3 using multiple Pcl3 shRNA targeting vectors
(Figure 2A and Figure S2A). Upon culturing multiple clones of
Pcl3 knockdown ESCs, we observed an increased percentage of
cells that were larger, less dense and displayed morphologies
consistent with differentiation (Figure 2B). These differentiated
morphologies suggested that Pcl3 may play a role in ESC
maintenance or self-renewal.
To assess whether Pcl3 contributes to ESC self-renewal, we
examined ESC markers including Oct4, Nanog, and alkaline
phosphatase. Consistent with the morphological changes, Oct4
and Nanog expression and protein levels were decreased in Pcl3
knockdown cells compared to control ESCs (Figure 2C–2D and
Author Summary
Embryonic development requires coordinated changes in
gene expression for the differentiation of specific cell
types. Regulated changes in gene expression are also
important for maintaining tissue homeostasis and pre-
venting cancer. Histone modifications contribute to the
control of gene expression by affecting chromatin
structure and the recruitment of regulatory proteins.
Polycomb repressive complex 2 (PRC2) catalyzes the
methylation of a lysine residue on histone H3, an early
step in gene repression. By investigating how PRC2 is
recruited to genes, we have found that Polycomb-like 3
(Pcl3), a protein upregulated in diverse cancers, is a
component of PRC2 that promotes its binding and
function at target genes. Consistent with roles for PRC2
in regulating stem cell behaviors, Pcl3 is important for
embryonic stem cell self-renewal. Thus, Pcl3 is a critical
regulator of gene repression and stem cell self-renewal
that acts by controlling PRC2 binding to target genes.
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alkaline phosphatase activity. Alkaline phosphatase staining was
slightly reduced in Pcl3 shRNA-treated ESCs (Figure S2C). To
quantitate this observation, we used a more sensitive colorimetric
assay, which confirmed that Pcl3 knockdown reduces ESC alkaline
phosphatase activity (Figure 2E). To confirm that these phenotypes
were specifically due to Pcl3 knockdown, we overexpressed a TAP-
tagged form of Pcl3 in wild type cells (Figure S2D–S2E).
Overexpression of Pcl3 in ESCs resulted in increased levels of
Oct4 and Nanog, further indicating that Pcl3 levels correlate with
ESC gene expression (Figure 2C).
To determine whether decreased expression of Oct4 and Nanog
affects self-renewal, we assessed Pcl3 knockdown ESCs for their
ability to generate colonies and found that Pcl3 shRNA ESCs
formed significantly fewer colonies than control cells (Figure 2F
and Figure S2F). These data suggest that Pcl3 promotes ESC self-
renewal. To substantiate this finding, we assayed the ability of wild
type and Pcl3-overexpressing cells to self-renew and form colonies.
We challenged wild type and Pcl3-overexpressing cells by growing
them in media containing reduced LIF. Pcl3-overexpressing ESCs
were able to form colonies modestly but significantly better than
wild type cells, further indicating that Pcl3 enhances ESC self-
renewal (Figure 2G).
In addition to its roles in self-renewal, PRC2 is critical for ESC
differentiation and embryonic development [22,24,29,30]. Besides
ESCs, Pcl3 is expressed in a number of differentiated tissues from
Figure 1. Pcl3 is a component of PRC2. (A) Protein levels of Suz12 and Suz12-TAP were measured in wild type, Suz12
Gt/+, Suz12
Rev/+, and
Suz12
Suz12TAP/+ cell lines by immunoblot. (B) Proteins detected by mass spectrometry that specifically co-purified with Suz12-TAP, their symbol,
unique hits, and percent coverage. (C) Pcl3-V5 binds to Suz12-TAP. Suz12
Suz12TAP/+ ESCs were transfected with empty vector, Pcl3-V5, or Mks1-V5
(control), and lysates were immunoprecipitated with FlagM2 and probed with anti-V5. (D) Pcl3-V5 binds Suz12, Ezh2, and Eed. Lysates from ESCs
transfected with empty vector, Pcl3-V5, and Mks1-V5 (control) vectors were subjected to immunoprecipitation with anti-V5. Samples were then
probed with anti-Suz12, anti-Ezh3, and anti-Eed. All westerns and co-immunoprecipitations were performed three times.
doi:10.1371/journal.pgen.1002576.g001
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Pcl3 is not well expressed in the adult nervous system, but it
expressed in the head during development [41]. To ascertain
whether Pcl3 is essential for ESC differentiation, we performed
teratoma and in vitro differentiation assays and assessed the
presence of all three germ layers. Teratomas from scramble and
Pcl3 shRNA-expressing cells were weighed and histologically
examined. While Pcl3 knockdown was maintained, we did not
observe differences in the size of the teratomas nor in the
formation of endodermal, ectodermal, or mesodermal derivatives
(data not shown and Figure 2H and Figure S2G). Moreover,
immunofluorescent staining revealed the presence of neural tissue
(NeuN and Tuj1), muscle (Actin), and skin basal cells (K14) in both
Pcl3 expressing and Pcl3 knockdown teratomas (Figure S2H).
In vitro differentiation of scramble and Pcl3 knockdown ESCs to
embryoid bodies resulted in a similar finding. Pcl3 shRNA-treated
EBs maintained Pcl3 knockdown and expressed markers of
neuroectoderm (Nestin), mesoderm (T-brachyury), and endoderm
(Hnf4) at least as well as control EBs, indicating that depletion of
Pcl3 does not abrogate the ability of ESCs to differentiate to cell
types of all three germ layers (Figure S2I). Thus, Pcl3 enhances
ESC self-renewal, but is not critical for ESC differentiation to the
three germ layers.
Pcl3 promotes trimethylation of H3K27
PRC2 accessory proteins, such as Aebp2, Pcl1, Pcl2 and Jarid2,
can either promote or inhibit PRC2 function [35–41,47,48,50,52].
To elucidate whether Pcl3 regulates PRC2 function, we measured
H3K27me3 levels in cells with diminished Pcl3. Pcl3 shRNA-
treated ESCs and EBs showed approximately 80% depletion of
H3K27me3 levels compared to scramble shRNA controls,
indicating that Pcl3 promotes PRC2 function (Figure 3A and
Figure S3A). To confirm this finding, we transfected ESCs with
either Suz12 or Pcl3 siRNAs and assessed H3K27me3 levels
[56,57]. qRT-PCR and immunoblot indicated that transfection of
Suz12 siRNAs diminished Suz12 expression in a dose-dependent
fashion (Figure S3B–S3C). Similarly, transfection of Pcl3 siRNAs
resulted in decreased Pcl3 expression and markedly reduced
H3K27me3, further demonstrating that Pcl3 promotes the
formation of H3K27me3 (Figure S3D and Figure 3B). As Pcl3
knockdown decreased H3K27me3, we assessed whether increased
Pcl3 resulted in a concomitant increase in H3K27me3. Indeed,
overexpression of Pcl3 in ESCs enhanced H3K27me3 levels
(Figure S2D–S2E and Figure 3C). Thus Pcl3 promotes trimethyla-
tion of H3K27.
Besides H3K27me3, histone modifications such as ubiquitina-
tion of lysine 119 of histone H2A (H2AK119Ub) and trimethyla-
tion of lysine 9 of histone H3 (H3K9me3) are involved in gene
repression [58–60]. In addition, H3K27me3 is inversely correlated
with acetylation on lysine 27 (H3K27ac) and marks bivalent
domains with H3K4me3 [11,61]. To assess whether Pcl3
participates in histone modifications apart from H3K27me3, we
analyzed histones from scramble and Pcl3 shRNA-treated cells for
H2AK119Ub, H3K9me3, H3K4me3, and H3K27ac. Levels of
H2AK119Ub, H3K9me3, H3K4me3, and H3K27ac were all
comparable between the control and Pcl3 knockdown ESCs,
indicating that Pcl3 is not involved in global histone modification,
but has a specific role in generating H3K27me3 (Figure 3D).
To confirm that Pcl3 shRNA-associated phenotypes were due to
decreased Pcl3 levels, we created a construct encoding a TAP-
tagged Pcl3 not recognized by the Pcl3 shRNAs. Pcl3-TAP was
detected by immunoblot and immunofluorescence and was able to
bind core PRC2 components as assessed by co-immunoprecipi-
tation, indicating that Pcl3-TAP functions similarly to wild type
Pcl3 (Figure 3E-3F and Figure S3E). Pcl3 expression in Pcl3-TAP-
expressing ESCs was nearly 60% of endogenous levels as
measured by qRT-PCR (Figure 3G). Re-expression of Pcl3-TAP
increased H3K27me3 levels in Pcl3 knockdown ESCs (Figure 3H).
These data indicate that Pcl3 promotes the formation of
H3K27me3 by PRC2.
Pcl3 promotes PRC2 binding and function at a subset of
PRC2 targets
To elucidate which genes depend upon Pcl3 for H3K27me3
formation and to investigate whether decreased H3K27me3 is a
result of Pcl3-dependent PRC2 binding, we performed ChIP-seq
for H3K27me3 and Suz12 in Suz12
Suz12TAP/+ cells expressing
either Pcl3 or control shRNA (GSE28325). Reads were aligned to
the mouse reference genome (NCBI Build 37, MM9) using bowtie,
and only uniquely aligned reads were considered for further
analysis (Figure S4A–S4B) [62].
Suz12 ChIP-seq was performed using the Flag tag of Suz12-
TAP. To validate this approach, we compared ChIP-seq of Suz12-
TAP using anti-Flag antibodies with ChIP-seq using anti-Suz12
antibodies in Suz12
Suz12TAP/+ cells and found they were equivalent.
We, thus, used FlagM2 to detect Suz12 binding in all the following
experiments. ChIP-seq with FlagM2 antibodies detected 95% of
previously reported Suz12 binding sites, indicating that this
approach accurately measured Suz12-TAP localization in the
genome (Figure S4C) [63,64]. In addition, we identified a number
of novel Suz12 binding sites, typified by less significant Suz12
ChIP-seq peaks (Figure S4C). These additional sites may reflect
weak Suz12 binding or may be an artifact of increased Suz12
levels.
Comparison of H3K27me3 ChIP-seq in scramble and Pcl3-
shRNA treated ESCs revealed a widespread decrease in
H3K27me3 levels in Pcl3 shRNA ESCs (Figure 4A). The decrease
in H3K27me3 as assessed by ChIP-seq was similar to, but not as
Figure 2. Pcl3 promotes ESC self-renewal. (A) Pcl3 expression levels measured by qRT-PCR in ESC clones transduced with scramble or multiple
Pcl3 shRNAs. Graph represents average expression from 3–6 different clones. (B) A portion of cells transduced with Pcl3 shRNA, but not scramble
shRNA, are larger, flatter, and less dense, signifying a decrease in ESC cell morphology. Scale bar 25 mm. These pictures are representative of 2–3
different clones of scramble and Pcl3 shRNA cells taken at three different time points. (C) Expression levels of Oct4 and Nanog in scramble, Pcl3 shRNA,
and Pcl3 overexpressing cells. (D) Quantification of Oct4 and Nanog staining in scramble and Pcl3 shRNA treated ESCs. +++indicates bright staining,
++indicates less bright staining, and+indicates little or no staining as assessed by eye. Graphs are representative of two clones and between 5–10
fields of view at 106magnification. (E) Alkaline phosphatase activity in scramble and Pcl3 shRNA cells. Graph represents average activity from 3–6
different clones in three experiments assayed in duplicate. (F) Quantification of the number of colonies formed per well from scramble and Pcl3
shRNA cells plated at 100 cells/well in a 6-well plate. Experiment was performed four times in duplicate with two clones each of scramble and Pcl3
shRNA ESCs. (G) Quantification of colonies formed by plating 100 cells/well of wild type and Pcl3 overexpressing cells in a 6-well plate. LIF was
reduced to 5% and was performed four times in duplicate. (H) Images of teratomas derived from scramble or Pcl3 shRNA ESCs containing all three
germ layers stained with hematoxylin and eosin. Abbreviations: EN-endoderm, NE-neuroectoderm, B-bone, C-cartilage, M-muscle, N-neural tissue.
Scale bar 25 mm. Error bars indicate standard deviation. Expression analysis experiments represent 3–4 experiments assayed in quadruplet. For all
experiments, asterisk denotes statistical significance of p,0.05. Staining was performed 2–3 times in two or more clones.
doi:10.1371/journal.pgen.1002576.g002
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PLoS Genetics | www.plosgenetics.org 5 March 2012 | Volume 8 | Issue 3 | e1002576Figure 3. Pcl3 promotes PRC2 function. (A) Immunoblot showing levels of H3K27me3 in multiple clones of scramble and Pcl3 shRNA ESCs and
EBs. (B) H3K27me3 levels in Suz12 and Pcl3 siRNA treated cells. (C) Increased levels of H3K27me3 as measured by immunoblot in cells overexpressing
Pcl3. (D) Immunoblot of H3K27me3, H2AK119Ub, H3K9me3, H3K4me3, and H3K27ac levels in histones from scramble and Pcl3 shRNA-expressing
cells. (E) Pcl3-TAP resistant to Pcl3 shRNA was reintroduced into Pcl3 shRNA cells, immunoprecipitated, and detected with anti-FlagM2. Suz12
Suz12TAP/+
cells were used as a positive control. (F) Pcl3-TAP binds Suz12, Eed, and Ezh2. Lysates from scramble and Pcl3 shRNA cells containing Pcl3-TAP were
immunoprecipitated with FlagM2 and immunoblotted for Suz12, Eed, and Ezh2. (G) qRT-PCR shows partial rescue of Pcl3 expression in Pcl3 shRNA
clones expressing Pcl3-TAP. Error bars indicate standard deviation. Graph represents average expression from 3–6 different clones in three
experiments assayed in quadruplet. (H) Immunoblot showing restoration of H3K27me3 levels in Pcl3 shRNA cells transduced with Pcl3-TAP. Histone
H3 and a-tubulin were used as loading controls. All westerns and immunoprecipitations were performed three or more times with 2–6 clones.
doi:10.1371/journal.pgen.1002576.g003
Polycomb-Like 3 Promotes PRC2 Function
PLoS Genetics | www.plosgenetics.org 6 March 2012 | Volume 8 | Issue 3 | e1002576profound as was detected biochemically. This may be attributable
to the inability of ChIP-seq to detect H3K27me3 in regions of
highly repetitive sequence, areas that are largely transcriptionally
silent. At approximately 85% of sites showing decreased
H3K27me3, Pcl3 knockdown cells also displayed reduced Suz12
binding compared to scramble controls, thus correlating decreased
Suz12 occupation with decreased PRC2 function (Figure 4A).
Indeed, Pcl3 knockdown significantly reduced Suz12 binding at
approximately 65% of PRC2 targets (Figure 4A, 4C). Sites with
decreased Suz12 binding outnumbered those with reduced
H3K27me3, indicating that Pcl3 knockdown preferentially affect-
ed Suz12 (Figure 4A).
The regions with the most decreased Suz12 occupation
following Pcl3 knockdown were among the most significant
Suz12 ChIP-seq peaks in control cells (Figure S4D). In contrast,
less significant Suz12 peaks were more likely to be unaffected by
Pcl3 knockdown (Figure S4D). The finding that the role of Pcl3 is
most pronounced on the most significant Suz12 binding sites is
consistent with a role for Pcl3 in mediating the recruitment of
additional Suz12 to regions of low level Suz12 binding.
Alternatively, changes in Suz12 binding may be more difficult to
detect at these less significant peaks.
Knockdown of Pcl3 diminished Suz12 binding to chromatin
particularly in areas of high gene density (Figure 4B). Accordingly,
chromosome 11, the chromosome with the highest gene density,
showed the most profound decrease in Suz12 binding and
H3K27me3 upon Pcl3 knockdown (Figure 4A and Figure S4E).
Consistent with PRC2 binding at repressed genes, sites with
decreased Suz12 binding in Pcl3 shRNA-treated ESCs were
inversely correlated with sites bound by the activating transcrip-
tion factors E2f1, c-Myc, Zfx, Klf4, and Ctcf, (Figure S4F and data
not shown, Fisher test p-value=9.5610
253, 3.7610
215,
1.2610
213, 4.0610
26, 3.6610
26, respectively) [63]. This is in
agreement with previous reports demonstrating nearly mutual
exclusion of Suz12 binding with regions bound by this group of
transcription factors [63].
As mentioned, Suz12 and H3K27me3 are present at bivalent
genes, genes with both active (H3K4me3) and repressive
(H3K27me3) histone marks in ESCs [11,65]. We found that
more than 80% of bivalent genes showed decreased Suz12 binding
upon Pcl3 depletion (Figure 4C) [11,65]. Among bivalent genes are
many developmental genes and microRNAs [64,66–70]. Using
ChIP-qRT-PCR, we confirmed that Pcl3 is important for
deployment of PRC2 at some of these developmental gene targets
and microRNAs including Hoxb7, Hoxb13, Hoxa3, Dusp4, Hand1,
mir-196b, mir-196a1, mir-10a, mir-132/mir-212, and mir-34a
(Figure 4D–4F) [66,67,69,71–74]. Suz12 ChIP-qRT-PCR also
confirmed that some Suz12 targets (e.g., Tle3, Tns1, and
Tmem151a) are unaffected by Pcl3 (Figure S4G). These data
further demonstrate that Pcl3 promotes PRC2 binding and
mediates PRC2 activity at a specific subset of PRC2 targets.
As H3K4me3 histone marks are also present at bivalent genes,
we extended our ChIP-qRT-PCR analysis to H3K4me3 to assess
whether Pcl3 depletion affects H3K4me3 formation. At genes
marked by H3K4me3 but not H3K27me3 (i.e., Eaf1, Ash21, Dcaf8,
Ift140, Glrx5), H3K4me3 levels were unchanged by Pcl3 depletion,
consistent with our finding that global H3K4me3 levels are
unchanged in Pcl3 shRNA ESCs (Figure S4H and Figure 3D).
H3K4me3 levels at approximately half of the bivalent genes
assayed showed modestly increased H3K4me3 levels (i.e., Acta1,
Hoxa3, Ebf2, mir196b, Hand1, Dusp4, Pmp22), while other genes
were unchanged (i.e., mir196a1, Hoxb7, Matb2, Pcdh7, Otx2,
Hoxb13) (Figure S4H). Thus, Pcl3 knockdown affects H3K4me3
levels specifically at a subset of bivalent genes.
Pcl3 co-localizes with Suz12 at many PRC2 targets to
promote H3K27me3
As Pcl3 binds core components of PRC2 and promotes Suz12
localization to its target genes, we investigated whether Pcl3 co-
localizes with Suz12 at target loci. To assess the distribution of
Pcl3 binding to chromatin in ESCs, we performed ChIP-seq of
Pcl3-TAP. Nearly all of the regions bound by Pcl3-TAP
overlapped with Suz12 targets, suggesting that Pcl3 co-localizes
at target genes as part of PRC2 (Figure 5A and S5A–S5B, Fisher
test p-value=1.5610
2306). Quantification revealed that Pcl3-TAP
bound nearly half of PRC2 targets, indicating that Pcl3 associates
with a subset of PRC2 complexes (Figure 5A). To substantiate the
co-localization analysis, we assessed which Suz12 sites overlapped
with Pcl3. Pcl3 and Suz12 co-localized predominantly at the most
significant Suz12 binding sites (Figure 5B). Suz12 sites at which
Pcl3 did not co-localize were typified by less significant Suz12
binding (Figure 5B). In addition, 80% of Pcl3 and Suz12 sites
overlapped with CpG islands compared to 65% of sites bound
only by Suz12, indicating that Pcl3 and Suz12 preferentially bind
at CpG islands (p-value=2.2610
216) [13].
To establish whether Pcl3 may directly contribute to PRC2
binding and function, we compared regions of Pcl3 binding to
areas of Pcl3-dependent Suz12 chromatin occupation and
H3K27me3 formation. Upon Pcl3 knockdown, 84% of Pcl3
binding regions showed decreased Suz12 binding, whereas less
than half of regions not bound by Pcl3 showed decreased Suz12
binding (Figure 5C–5E). In addition, Pcl3 binding regions showed
a near two-fold enrichment for decreased H3K27me3 upon Pcl3
knockdown, as compared to regions not bound by Pcl3 (Figure 5E).
ChIP-qRT-PCR for Pcl3 confirmed that Pcl3 bound to many of
the same genes that exhibited decreased Suz12 binding and
H3K27me3 upon Pcl3 knockdown (Figure 4F and Figure 5F).
These data indicate that genes bound by Pcl3 are nearly twice as
likely to have reduced Suz12 binding and H3K27me3 upon Pcl3
knockdown. Thus, Pcl3 not only co-localizes with Suz12 at many
PRC2 targets, but also promotes Suz12 binding and PRC2
function.
Pcl3 regulates gene expression at a subset of PRC2
targets
Inhibition of PRC2 core components and complete abrogation
of H3K27me3 dramatically alter gene expression, whereas
inhibition of accessory proteins such as Jarid2 result in more
modest changes [22,29,30,40]. To test whether Pcl3 affects gene
expression, multiple scramble and Pcl3 shRNA clones were
analyzed by microarray. Nearly 130 genes displayed altered
expression upon Pcl3 knockdown. Unexpectedly, given that PRC2
functions to repress gene expression, nearly three times as many
genes were down-regulated upon Pcl3 knockdown as were up-
regulated (Table S1). Notably, we identified more than half of the
upregulated genes as PRC2 targets, which correlated well with
depleted Suz12 binding and H3K27me3 (Figure S6B). We
confirmed the microarray data by measuring gene expression by
qRT-PCR for several genes (Figure 6SA).
Given that Pcl3 knockdown increases the proportion of
differentiated cells, we tested whether the presence of differenti-
ated cells masked changes in ESC gene expression by pre-plating
twice to remove differentiated cells. Microarray analysis revealed
that approximately 120 genes showed differential expression in the
Pcl3 shRNA cells compared to control after removal of
differentiated cells (Table S2). qRT-PCR assessment of a subset
of the affected genes confirmed the microarray results (Figure
S6B). Of these Pcl3-regulated genes, almost two thirds were up-
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that Pcl3 participates in the repression of genes in ESCs, only a few
of these genes also displayed decreased Suz12 binding and
H3K27me3 levels (i.e., Hand1, Acta1, and Pmp22) (Table S2,
Figure 4E–4F and Figure S6B) which may be attributable to the
necessity of culturing Pcl3 shRNA ESCs for an extended time
before subjecting them to microarray analysis.
Pcl3 regulates Suz12, but not complex stability
Loss of core PRC2 components can destabilize the complex
[25,29]. To assess whether loss of Pcl3 affects complex stability, we
tested whether the complex could form in the absence of Pcl3. All
components, Suz12, Ezh2, and Eed, were found by co-
immunoprecipitation to bind each other in both scramble and
Pcl3 shRNA-expressing cells, suggesting that Pcl3 is not required
for assembly or stabilization of the core complex (Figure 6A).
To determine whether depleting Pcl3 influences levels of PRC2
components, we assessed the quantity of PRC2 core components
in Pcl3 shRNA-treated ESCs. Interestingly, suppression of Pcl3
significantly lowered Suz12 mRNA and protein levels without
affecting levels of Eed or Ezh2, suggesting that Pcl3 regulates
Suz12 (Figure 6B–6C). Overexpressing Pcl3 caused a concomitant
increase in Suz12 mRNA and protein levels (Figure 6D–6E). As
Suz12 is not a known PRC2 target and Pcl3 is not enriched at the
Suz12 locus, effects on Suz12 expression by Pcl3 are likely indirect
(Figure S6D) [7,75,76].
The Tudor domain of Pcl3 is critical for its function
Polycomb-like proteins contain three domains, an amino-
terminal Tudor domain and two carboxy-terminal PHD fingers
(Figure 7A). Although the carboxy PHD finger of Pcl2 promotes
PRC2 recruitment, the Tudor domain and amino PHD finger of
Pcl2 are not required for its regulation of PRC2 [41,77]. In
contrast, the Tudor domain and carboxy-terminal PHD finger of
human Pcl3 are important for binding Ezh2 and self-association
[53].
NMR studies indicate that the Drosophila Polycomb-like Tudor
domain lacks a complete aromatic cage, needed to bind
methylated lysines or arginines on histones [78]. Interestingly, a
comparison of Drosophila Pcl Tudor domain sequence to those of
mammalian Pcl Tudor domains suggests that mammalian
Polycomb-like proteins may be able to form complete aromatic
cages [78]. In particular, the conserved residues W48,Y54, F72,
D74, and S76 are implicated in histone binding (Figure 7A–7B)
[78]. To ascertain if these Tudor domain residues are required for
Pcl3 function, we mutated two sets (W48;Y54 and F72;D74), as
well as a control set of residues (N75;Y78) within Pcl3-TAP
(Figure 7A–7B) [78]. These mutant forms of Pcl3 were expressed
in Pcl3 knockdown ESCs to see if they could rescue H3K27me3
levels as well as wild type Pcl3-TAP (Figure 7C). Similar to wild
type Pcl3-TAP, Pcl3-TAP N75S;Y78S was able to promote
H3K27me3 formation (Figure 7D). In contrast, Pcl3-TAP
W48A;Y54A and Pcl3-TAP F72S;D74S did not restore
H3K27me3 formation (Figure 7D). Thus, W48;Y54 and
F72;D74, two pairs of residues implicated in histone binding, are
necessary for Pcl3 function, while the control N75;Y78 pair is
dispensable.
To discern whether these Tudor domain residues are necessary
for Pcl3 incorporation into PRC2, we assessed whether Suz12 co-
immunoprecipitated with Pcl3-TAP W48A;Y54A, Pcl3-TAP
F72S;D74S, and Pcl3-TAP W48A;Y54A. All mutant forms of
Pcl3 associated with Suz12, indicating that these residues are not
required for binding PRC2 (Figure 7C). Thus, W48;Y54 and
F72;D74 are essential for Pcl3 promotion of H3K27me3
formation, but not for Pcl3 incorporation into PRC2.
Pcl3 and Pcl2 are part of distinct PRC2 complexes with
overlapping targets
While Pcl1 is minimally transcribed in ESCs, Pcl2 is highly
expressed and binds a subset of PRC2 target genes [41]. To assess
whether depletion of Pcl3 affects Pcl1 or Pcl2, we measured Pcl1
and Pcl2 expression in scramble and Pcl3 knockdown ESCs. Pcl1
was expressed at extremely low levels but showed no difference
upon Pcl3 knockdown (Figure 8A). Likewise, we found that Pcl2
levels were similar between scramble and Pcl3 shRNA-treated
ESCs (Figure 8A).
Although Pcl2 and Pcl3 are both expressed in ESCs, it is unclear
if they participate in same complex or regulate the same genes. To
assess whether Pcl3 and Pcl2 incorporate into the same complex or
exist in distinct PRC2 complexes, we tested Pcl3 and Pcl2
association by co-immunoprecipitation. Flag immunoprecipitation
confirmed that Pcl2 and Pcl3 both bind Suz12 (Figure 8B).
However, Pcl3-TAP did not immunoprecipitate Pcl2, suggesting
that Pcl2 and Pcl3 do not associate within the same PRC2
complex (Figure 8B). To substantiate these data, we performed the
reciprocal immunoprecipitation and found that Pcl2 immunopre-
cipitated Suz12-TAP but not Pcl3-TAP. These findings indicate
that Pcl2 and Pcl3 both interact with the core PRC2 complex, but
not with each other, suggesting that Pcl2 and Pcl3 participate in
distinct PRC2 complexes.
To elucidate whether Pcl3 and Pcl2 bind distinct or overlapping
sets of targets, we compared our Pcl3 ChIP-seq data with
previously generated Pcl2 ChIP-seq data and found that Pcl3
and Pcl2 binding overlaps at 60–70% of sites [41]. This extensive
overlap raises the possibility that many genes may be regulated by
both Pcl3 and Pcl2.
Like Pcl3, Pcl2 can promote PRC2 activity at some loci and in
some cell types [41,47,77,79]. To test whether Pcl2 can
compensate for Pcl3 function, we analyzed whether Suz12 binding
at Pcl2 targets was affected by Pcl3 depletion. Of sites bound by
both Suz12 and Pcl2, 86% showed decreased Suz12 binding upon
Pcl3 depletion (Figure 8C–8D), suggesting that Pcl2 cannot
compensate for Pcl3 function at Pcl2 sites.
Figure 4. Pcl3 affects Suz12 binding at a subset of PRC2 targets. (A) Graph depicts chromosome-wise distributions of decreased Suz12 and
H3K27me3 ChIP-seq reads upon Pcl3 knockdown (Pcl3 KD) relative to scramble control. Many regions display both Suz12 and H3K27me3 depletion
(blue). Independently decreased Suz12 occupancy and H3K27me3 are marked in cyan and orange, respectively. ChIP-seq peaks were called at a
Skellam distribution p-value cutoff of 10
27. Fisher test p-value was 3.2610
241 for the overlap of H3K27me3 with Suz12 sites. (B) Reduced Suz12 and
H3K27me3 ChIP-seq read density upon Pcl3 knockdown is correlated with gene density. Pearson correlation is 0.40 for Suz12 and 0.26 for H3K27me3.
(C) 65% of PRC2 targets show decreased Suz12 binding upon Pcl3 knockdown, particularly bivalent genes (Fisher test p=4.9610
2250). (D) Binding of
Pcl3 and Suz12, and histone mark profiles of H3K27me3 at the Hoxa3 gene and in the region surrounding mir-196a1. Units are number of reads/
250 bp. (E) Log fold-changes in Suz12 and H3K27me3 ChIP-seq read density at specific genes in Pcl3 knockdown cells compared to scramble control.
(F) Levels of Suz12 binding and H3K27me3 in Suz12
Suz12TAP/+ cells expressing either scramble or Pcl3 shRNA assessed by FlagM2 or H3K27me3 ChIP-
qRT-PCR. ChIP-qRT-PCR experiments were performed at 3–4 times and assayed in quadruplicate. Error bars indicate standard deviation. Decreases are
statistically significant, p,0.005.
doi:10.1371/journal.pgen.1002576.g004
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[41,47,77,79]. To further investigate the functional relationship
between Pcl2 and Pcl3, we assessed Suz12 binding and
H3K27me3 at regions bound by both Pcl2 and Pcl3. If Pcl2 and
Pcl3 act redundantly to promote Suz12 binding, sites bound by
both would not show significant decreases in Suz12 binding upon
Pcl3 knockdown as Pcl2 would be functional at these sites.
Conversely, if Pcl2 hinders PRC2 binding while Pcl3 promotes
PRC2 binding, Suz12 binding at shared Pcl2 and Pcl3 sites would
be more dramatically reduced upon Pcl3 knockdown, as Pcl3
would no longer be able to counterbalance Pcl2 function. Among
regions bound by Suz12, Pcl2, and Pcl3, 95% showed Suz12
depletion upon Pcl3 knockdown (Figure 8C–8D). Moreover, Pcl3-
dependent Suz12 sites often co-localized with Pcl2 and Pcl3
binding, whereas Pcl3-independent Suz12 sites tended to be more
distant from Pcl2 and Pcl3 binding sites (Figure 8E). In addition,
88% of Pcl2 and Pcl3 shared sites showed diminished H3K27me3.
Thus, these data suggest that not only does Pcl2 not compensate
for Pcl3, but also that Pcl2 may hinder Suz12 binding and
H3K27me3 at Pcl2 and Pcl3 shared binding sites.
Pcl2 and Pcl3 co-localize with Suz12 at CpG islands
Polycomb repressive elements (PREs), binding sites that recruit
Polycomb proteins, have been well-described in Drosophila, but
few have been found in mammals [80–84]. Nevertheless,
mammalian PRC2 is known to preferentially bind CpG islands
[13,19,85]. Similarly, we found that 86% of Pcl2 and Pcl3 co-
localization sites were found in CpG islands [13,41,86]. To assess
whether distinct DNA sequence motifs required for Pcl2 and Pcl3
recruitment exist, we searched for sequence features that can
discriminate DNA sequences in genomic regions bound by both
Pcl2 and Pcl3. We scanned 500 base pair regions surrounding Pcl3
ChIP-seq peaks for prevalent DNA sequences and identified two
enriched 10- and 14-mer motifs (Figure 9A). Motif 1 consisted of
three consecutive G-C dinucleotides with two nucleotides on either
side containing modest GC enrichment. Motif 2 contained two G-
C-rich regions separated by seven nucleotides with little to no GC
enrichment. Thus, motifs commonly found in Pcl2 and Pcl3
binding regions contain short GC sequences surrounded by
dissimilar sequence.
To assess whether these motifs were predictive of Pcl2 and Pcl3
binding sites, Pcl3-dependent Suz12 binding sites or CpG islands,
we constructed a position specific scoring matrix (PSSM) for each
motif. The occurrence of motifs 1 and 2 correlated more tightly
with Pcl3-dependent Suz12 binding sites that co-localize with both
Pcl2 and Pcl3 binding sites than with Suz12 sites that are not
associated with Pcl2 and Pcl3 binding, nor depend on Pcl3 activity
(Figure 9B–9C). In addition to the maximum PSSM scores, we
also computed the CpG density of each site and used these three
sequence features to build a support vector machine classifier to
help predict whether specific motifs would co-localize with Pcl2
and Pcl3 binding and areas of Suz12 depletion following Pcl3
knockdown (Figure 9D). The classifier had cross-validation
accuracy of 75%, indicating that CpG density, Motif 1, and
Motif 2 together account for the majority of Pcl3-dependent PRC2
binding. Even though the vast majority of Pcl2 and Pcl3 binding
sites were found in CpG islands, they seemed to avoid regions with
the highest CpG density, concordant with the moderate GC
content of the motif sequences (Figure 9B–9D). These data
indicate that Pcl2 and Pcl3 may utilize specific binding motifs to
recruit PRC2 to form H3K27me3 at CpG islands.
Discussion
In an effort to understand the mechanisms that regulate PRC2,
we have discovered that a PRC2 interacting protein, Polycomb-
like 3, promotes ESC self-renewal and mediates PRC2 binding at
a number of targets genes. In ESCs, Pcl3 promotes the expression
of multiple markers of pluripotency. Consistent with a functional
role for Pcl3 in PRC2, Pcl3 also promotes H3K27me3 formation.
ChIP-seq analyses revealed that diminished Pcl3 decreased Suz12
binding, particularly in regions where Pcl3 co-localizes with
Suz12, suggesting that one way that Pcl3 promotes PRC2 activity
is by mediating PRC2 binding to chromatin. Pcl3 likely resides in
a PRC2 complex distinct from that which incorporates its paralog,
Pcl2, but both PRC2 complexes have overlapping targets
predominantly at CpG-rich regions. Despite their overlap and
homology, Pcl2 cannot compensate for Pcl3 and may inhibit
PRC2 at shared genes, as regions of Pcl2 and Pcl3 co-binding
show the most significant reduction in Suz12 binding upon Pcl3
knockdown.
Pcl3 likely has a direct role in promoting PRC2 binding at select
targets, as it 1) biochemically interacts with PRC2, 2) binds to
genomic regions overlapping with Suz12, and 3) is predominantly
required for genomic Suz12 binding at Pcl3 binding sites. This co-
occurrence and dependence of PRC2 on Pcl3 suggests that the
biochemical interaction of Pcl3 with PRC2 underlies its role in
PRC2 binding. In addition to this direct role for Pcl3 in PRC2
binding to chromatin, the reduction in Suz12 binding upon Pcl3
knockdown may also be partially attributable to decreased Suz12
levels. Suz12 is not known to be regulated by PRC2 and Pcl3 does
not bind the Suz12 locus, indicating that this regulation of Suz12
by Pcl3 is likely to be indirect.
Many bivalent genes are involved in regulating ESC differen-
tiation [8–15]. However, we observed that Pcl3 promotes ESC
self-renewal, but is not required for differentiation into cell types of
all germ layers. As we have found that Pcl3 promotes H3K27me3
at a subset of bivalent genes, it is possible that Pcl3 predominantly
represses bivalent genes involved not in cell fate decisions in
differentiating cells, but in genes that promote differentiation itself.
Thus, Pcl3 depletion would derepress genes that promote
differentiation, leading to specific defects in self-renewal. Con-
versely, Pcl3 overexpression may lead to increased self-renewal by
Figure 5. Pcl3 localizes to PRC2 targets. (A) Heatmaps showing Pcl3 and Suz12 ChIP-seq read density in counts per 100 bp around Pcl3 peak
centers. Approximately 44% of Suz12 targets are bound by Pcl3-TAP. Each row corresponds to a Pcl3 ChIP-seq peak with rows ranked by Pcl3 peak
significance (assessed by the Skellam distribution p-values). (B) Graph of 2log p-values indicating that the most significant Suz12 ChIP-seq peaks
overlap with Pcl3, while regions containing less significant Suz12 ChIP-seq peaks are not bound by Pcl3. Wilcoxon p-value,1e
2306 for the difference
in the distribution of ChIP-seq 2log p-values. (C) Pcl3 co-localizes with Suz12 depletion sites (blue). Regions containing only Suz12 depletion or only
Pcl3 binding are indicated in cyan and orange respectively. (D) 84% of sites bound by Suz12 and Pcl3 show decreased Suz12 binding upon Pcl3
(Fisher test p-value=1.5610
2306). Two binding sites were considered to be overlapping if their peak centers were within 2 kb from each other. (E)
Suz12 (Wilcoxon p-value,1e
2306) and H3K27me3 (Wilcoxon p-value=3.7e
236) co-localizing with Pcl3 show much more significant depletion
compared to Suz12 and H3K27me3 targets not bound by Pcl3. Depletion score=2log p-value (read counts before/after Pcl3 KD). (F) Genes and
microRNAs bound by Pcl3-TAP measured by FlagM2 ChIP-qRT-PCR. The graph depicts average fold enrichment over control levels for three different
clones in three different experiments assayed in quadruplet. Error bars indicate standard deviation. All increases are statistically significant, p,0.04.
doi:10.1371/journal.pgen.1002576.g005
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expression of self-renewal genes such as Nanog.
Consistent with this idea, we found that inhibiting Pcl3 function
increased H3K4me3 levels and expression at some but not all
bivalent genes. Pcl3-dependent H3K4me3 may regulate be the
genes that promote differentiation upon Pcl3 inhibition. Thus,
diminishment of Pcl3 does not derepress all PRC2 targets, but
instead may derepress a specific subset that restrain ESC
differentiation.
PRC2 is recruited to chromatin by multiple mechanisms
including interactions with CpG islands, non-coding RNAs, and
histone binding proteins [36,38,39,87–89]. Our analysis of Suz12
and Pcl3 binding sites revealed that they associate with CpG-
enriched regions, particularly two CpG-rich DNA sequence
Figure 6. Pcl3 regulates Suz12, but not complex stability. (A) PRC2 components associate in the absence of Pcl3 based on co-
immunoprecipitation. b-actin used as a loading control. (B) Protein levels of Suz12, Ezh2, and Eed in scramble and Pcl3 shRNA clones as measured by
immunoblot. Experiments were performed with 3–6 scramble and Pcl3 shRNA clones each. (C) Expression levels of Suz12, Ezh2, and Eed in scramble
and Pcl3 shRNA measured by qRT-PCR. (D) Suz12 mRNA levels measured by qRT-PCR in wild type and Pcl3 overexpressing cells. (E) Suz12 protein
levels in wild type cells and wild type cells overexpressing Pcl3-TAP. All immunoblot and co-immunoprecipitation experiments were performed 2–5
times. All expression analysis represents three experiments assayed in quadruplicate. Error bars represent standard deviation, and asterisk indicates
statistical significance of p,0.005.
doi:10.1371/journal.pgen.1002576.g006
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PLoS Genetics | www.plosgenetics.org 12 March 2012 | Volume 8 | Issue 3 | e1002576Figure 7. Pcl3 requires Tudor domain residues for function. (A) Schematic of Pcl3 architecture including Tudor and PHD domains. Size of
domains are indicated by amino acid number, but schematic is not to scale. Orange boxes indicate mutated residues. (B) Sequence alignment of the
Tudor domain of human and mouse Polycomb-like homologues. Bottom graph indicates the degree of conservation at each residue. Green circles
indicate putative histone binding sites. Orange squares indicate mutated residues. (C) Mutant Pcl3-TAP protein is detected at similar levels to wild
type Pcl3-TAP by immunoprecipitating and probing with anti-FlagM2. Mutant Pcl3-TAP can bind Suz12 as well as wild type Pcl3-TAP by co-
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areas with minimal GC content, indicating that Pcl proteins do not
associate with the most GC-rich regions, but rather with regions of
moderate GC content and containing motifs 1 or 2. Our support
vector machine classifier supported these findings by showing that
Pcl2 and Pcl3 binding sites that overlap with Pcl3-dependent
Suz12 bound sites localize in areas with moderate CpG density.
The finding that Pcl proteins associate with CpG islands is
consistent with prior observations that PRC2 binds to CpG islands
and demonstrates that Pcl3 may participate in PRC2 recruitment
to CpG islands [13,19,85].
Pcl proteins contain multiple domains by which they can
associate with chromatin, including a Tudor domain and two
PHD fingers implicated in recognizing methylated or unmethy-
lated histone lysines or arginines [90–92]. Recent work has
implicated several residues of the Pcl Tudor domain in histone
binding [78]. Mutating two sets of these Pcl3 Tudor domain
residues revealed that they are essential for Pcl3-dependent PRC2
activity. As these mutant forms were able to incorporate into
PRC2, they may be acting as dominant negatives and poisoning
the complex or as loss-of-function mutants by creating less-
functional complexes. Thus, these mutants may perturb PRC2
function through inhibition of complex recruitment to histones or
by decreasing PRC2 methyltransferase activity.
Two other paralogs of Pcl exist in mammals. Pcl1 is expressed
minimally in ESCs, and Pcl2 has been implicated in either
promoting or inhibiting PRC2 in a gene- and cell type-dependent
manner [41]. In ESCs, Pcl2 restrains PRC2 activity globally, and
in MEFs, Pcl2 inhibits PRC2 recruitment to certain loci
[41,47,77]. In an effort to understand the relationship between
these paralogs, we found that Pcl2 and Pcl3 do not associate and
likely participate in separate PRC2 complexes, which both bind a
subset of PRC2 targets. If Pcl2 and Pcl3 both promoted PRC2
binding and activity at these targets, we might expect Pcl2 to
compensate in Suz12 binding and H3K27me3 upon loss of Pcl3.
Instead, we observed the greatest dependence of Suz12 binding on
Pcl3 at regions also bound by Pcl2, suggesting that Pcl2 may
inhibit PRC2 binding at these genes (Figure 9E).
It is unlikely that Pcl2 requires Pcl3 for activity as knockdown of
Pcl2 and Pcl3 in ESCs results in opposite phenotypes, further
suggesting that these two paralogs have distinct and opposing
functions. For example, Pcl2 destabilizes Ezh2, whereas Pcl3
enhances Suz12 protein levels without affecting Ezh2 [41].
Moreover, Pcl2 and Pcl3 have opposite effects on ESC self-
renewal and differentiation. Pcl2 inhibits expression of Oct4, Sox2,
and Nanog and promotes ESC differentiation [41]. In contrast, Pcl3
promotes Oct4 and Nanog levels and ESC self-renewal. Finally,
whereas the Tudor domain of Pcl2 is dispensable for its function,
the Pcl3 Tudor domain is essential for mediating PRC2 activity
[41].
Despite its global requirement to restrain H3K27me3 levels in
ESCs, Pcl2 can promote H3K27me3 and PRC2 binding at certain
sites [41,47]. Pcl2 and Pcl3 overlap at approximately 65% of sites,
indicating that each binds separately at a third of their sites. While
our data indicates that Pcl3 and Pcl2 function oppositely at Pcl2
and Pcl3 targets, one possibility is that Pcl2 promotes PRC2
activity at regions devoid of Pcl3 (Figure 9E) [41].
Based on these data, we propose that Pcl2 and Pcl3 have
opposing functions on PRC2 binding and activity at sites they co-
regulate (Figure 9E). At sites that Pcl2 and Pcl3 individually
regulate, each may both promote PRC2 binding. Upon loss of
Pcl3, sites dependent upon Pcl3 for promoting PRC2 function lose
H3K27me3, and this loss may be exacerbated by negative
regulation of PRC2 by Pcl2 at sites that Pcl2 and Pcl3 regulate
together (Figure 9E). Thus, Pcl2 and Pcl3 may function
antagonistically at shared sites, but promote H3K27me3 at sites
regulated by a single Pcl (Figure 9E). This model predicts that the
minority of sites at which Pcl2 promotes H3K27me3 levels will be
regions not bound by Pcl3. The model does not resolve how Pcl2
could promote PRC2 activity at regions where Pcl3 does not bind,
but could inhibit PRC2 activity at shared sites upon Pcl3
knockdown. One possibility is that regions of Pcl2 and Pcl3 co-
occupancy are characterized by an inhibitory PRC2 activity
independent of Pcl2.
Both bivalency and gene repression at CpG promoters are
dependent on PRC2 activity. In ESCs, CpG promoters may be
poised for activation, reflected by their ability to bind RNAPII
even when inactive [93]. Pcl3-mediated deployment of PRC2 at
CpG islands may be one mechanism by which these poised CpG
promoters are kept in check in ESCs. When cell type-specific
promoters are being repressed during development, Pcl3 may
promote PRC2 binding at many of these same CpG islands in
ways that recruit PRC1 to ensure more permanent transcriptional
silencing.
Understanding how Pcl proteins regulate PRC2 at specific
genes may also be critical to elucidating gene misregulation during
cancer. Many cancers show a global silencing at gene promoters,
particularly at CpG islands [94,95]. Ezh2 is one of the most
commonly misregulated genes in cancer, and recent work has
shown that Pcl3 is misregulated in diverse cancers as well [34,96].
Similar to our findings in ESCs, Pcl3 upregulation in cancer cells
may promote PRC2 recruitment, inhibiting the expression of
genes that inhibit self-renewal, and leading to inappropriate cell
proliferation. Thus, studying the role of Pcl3 in PRC2 function in
ESCs may provide insight into how Pcl3 up-regulation returns
cancer cells to transcriptional states and self-renewal capacities
similar to those of ESCs.
Materials and Methods
Tissue culture
Mouse E14 embryonic stem cells were grown as described
previously [54,97]. Bay Genomics gene trap line XG122 was used
for the establishment of Suz12
Suz12TAP/+ ESCs [54].
Lentiviral infection
ESCs were trypsinized and 1 ml of cells at 10
5/ml were plated
into one well of a 6-well plate along with 15 ml of concentrated
lentivirus (Open Biosystems RMM4534 and Sigma SHC002). The
plate was shaken every ten minutes for one hour and then
incubated overnight at 37uC. Media was changed the next day
and selection was started (2 mg/ml puromycin, 50 mg/ml zeocin).
Cells were selected for six days, clones were picked, and
immunoprecipitation. (D) Pcl3-TAP W48A;Y48A and Pcl3-TAP F72S;D74S do not support H3K27me3 whereas Pcl3-TAP N75S;Y78S does. Immunoblot
displaying H3K27me3 levels in histones purified from cells expressing Pcl3 shRNA, Pcl3 shRNA with Pcl3-TAP, and Pcl3 shRNA with mutant Pcl3-TAP.
Histone H3 and a-tubulin were used as loading controls. Each lane represents a different clone. All westerns and immunoprecipitations were
performed 3–4 times with at least two clones from each mutant.
doi:10.1371/journal.pgen.1002576.g007
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constructs were tested and all gave similar results.
Transfection
Cells were transfected using Lipofectamine 2000 (Invitrogen
11668-019). Briefly 0.5 mg of DNA was combined with 1 mlo f
Lipofectamine in 50 ml of Optimem and incubated for 20 min.
ESCs were trypsinized and 2610
5 were plated into a well of a 6-
well along with Lipofectamine mixture. Cells were incubated for
18 hrs followed by media replacement. For siRNAs, 300 ng
siRNA and 3 ml Lipofectamine in 300 ml of Optimem was used for
the Lipofectamine mixture.
In vitro prepared siRNA pools
Libraries of siRNAs were made as previously described [56,57].
Purification and mass spectrometry of Suz12
Suz12-TAP and bound proteins were purified and subjected to
mass spectrometry as previously described [79].
Histone purification
Histones were purified from ESCs as previously described [98].
Immunoprecipitation and Western immunoblot
Cells were treated as previously described [99]. For Flag
immunoprecipitation, 40 ml of FlagM2 resin (Sigma A2220) was
added to 800 mg protein lysate overnight. All experiments were
performed three or more times. Pcl3 knockdown experiments
contained at least two scramble and Pcl3 shRNA clones.
Antibodies
The list of antibodies used for immunoblotting and immuno-
fluorescence is included in Text S1.
Immunofluorescence and staining
Cells were plated on coverslips coated with poly-lysine and
Matrigel (BD Biosciences) and stained as previously described
[99].
Expression analysis
Expression was assayed as described previously [99]. Expression
levels are representative of three or more experiments using 2–6
different clones and assayed in quadruplet. Statistical significance
was determined using an unpaired student’s t-test. Primers for
qRT-PCR and ChIP is included in Text S1.
DNA mutagenesis
Point mutations were created using the Agilent site-directed
mutagenesis kit (Quikchange II XL Site-Directed Mutagenesis,
Agilent Technologies, 200522) and Quikchange primer design
application.
Alignment
Polycomb-like paralog alignment was performed using CLC
sequence viewer (CLC Bio).
Alkaline phosphatase activity assay
Alkaline phosphatase activity was determined by staining and
using StemTag Alkaline Phosphatase Activity Kit (Cell Biolabs
CBA-301). ESCs were plated with ES media containing LIF and
allowed to grow to 80% confluency. For staining, ESCs were fixed
in 0.5% glutaraldehyde and washed three times in HBS followed
by three washes in AP buffer (100 mM Tris pH 9.5, 100 mM
NaCl, 50 mM MgCl2). NBT/BCIP substrate was added and
samples were incubated at 37u for 10 minutes. Reaction was
stopped with 50 mM EDTA pH5.1 in PBS, and pictures were
taken. For the StemTag colorimetric assay, cells were lysed,
incubated with assay substrate, and assayed for absorbance.
Experiment was performed in duplicate three independent times.
Colony formation assay
ESCs were trypsinized, counted, and plated at 100 cells/well of
a 6-well. After 8 days, colonies were stained with methylene blue
and quantitated. For wild type and Pcl3-overexpressing cells, ESCs
were grown in 5% of normal LIF concentration. Experiment was
performed in duplicate four independent times.
Teratoma formation
ESCs were trypsinized, counted, and prepared to a concentra-
tion of 6.7610
6 cells/ml. 300 ml( 2 610
6) cells were injected
subcutaneously into severely combined immunodeficient (SCID)
mice and allowed to form teratomas for 2–3 weeks. Tumors were
removed and divided for paraffin sections, frozen sections, and
RNA. Teratomas were formed from two clones each of scramble
and Pcl3 shRNA ESCs.
Microarray
Sample preparation, labeling, and array hybridizations were
performed according to standard protocols from the UCSF Shared
Microarray Core Facilities and Agilent Technologies (http://
www.arrays.ucsf.edu and http://www.agilent.com). See Text S1
for more detailed description. The microarray was performed in
2–6 clones from scramble and Pcl3 shRNA ESCs.
ChIP
ChIP-seq experiments were done as previously described with
500 mg of chromatin and 5 mg of antibody [100]. ChIP-qRT-PCR
experiments were performed at least two times with 10
7 ESCs and
10 mg of antibody. Antibodies used for immunoprecipitation
Figure 8. Pcl3 and Pcl2 participate in separate PRC2 complexes but overlap at many PRC2 binding sites. (A) Pcl2 and Pcl1 mRNA levels
are not significantly different between scramble and Pcl3 shRNA cells. Graph represents average expression from three different experiments in 2–6
different clones and assayed in quadruplet. Error bars indicate standard deviation. (B) Co-immunoprecipitation showing that immunoprecipitated
Suz12-TAP associates with Pcl2 whereas immunoprecipitated Pcl3-TAP does not. Pcl3-TAP does bind Suz12 as seen in the lower blot. a-tubulin was
used as a loading control. Reciprocal co-immunoprecipitations showing a Pcl2-specific association with Suz12-TAP but not an association between
Pcl2 and Pcl3-TAP. b-actin was used as a loading control. Each blot is representative of three different experiments. (C) Graph depicts chromosome-
wise distributions of Pcl2 co-localization with sites depleted of Suz12 following Pcl3 knockdown (blue). Regions containing only Suz12 depletion and
only Pcl2 binding are indicated in cyan and orange respectively. (D) Decreased Suz12 binding upon Pcl3 knockdown occurs at 86% of targets bound
by Suz12 and Pcl2 (Fisher test p-value,p,10
2300). Of sites bound by Pcl2 and Pcl3, 95% show decreased Suz12 binding upon Pcl3 knockdown. (E)
Pcl2 and Pcl3 binding sites co-localize with regions of Suz12 depletion upon Pcl3 knockdown (top), whereas Pcl2 and Pcl3 binding sites reside far
from unaffected Suz12 binding sites (bottom). The figure shows the joint probability density of the nearest Pcl2 and Pcl3 locations relative to Suz12.
Darker color represents higher probability density. Bivariate normal kernel density estimates were obtained by using the smoothScatter function inR .
The distance coordinates were transformed to base pairs sign (Pcl22Suz12) log10 |Suz122Pcl2|, and similarly for Pcl3.
doi:10.1371/journal.pgen.1002576.g008
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using a 9th order Markov background dependence model [86]. Two examples of 10- and 14-mer enriched motifs are shown. (B–C) Smoothed scatter
plots of maximum position specific-scoring matrix (PSSM) scores for the two motifs and CpG density are shown for (B) Suz12 binding sites depleted
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088k6018), anti-Flag M2 (Cell Signaling, 2368), anti-Suz12
(Upstate, 07-379), and anti-H3K4me3 (Millipore clone MC315
04-745) antibodies. More detailed descriptions are included in
Text S1.
ChIP-seq analysis
The data consisted of short reads from single-end 30-nucleotide
sequencing. The short reads were aligned to the reference mouse
genome (version MM9) by using bowtie with the parameters -n 2 -
y –best -m 1 [62]. The summary of alignment results is provided in
Figure S4A. Paired samples were normalized by equalizing the
number of reads in the background: partial sums of order statistics
of binned read counts in paired samples were computed, and the
ratios of the partial sums were plotted as a function of the quantile
cutoff in the sum (Figure S4B). The point where the curve deviates
significantly from linearity was found by fitting a linear regression
using half of the data between the 10th and 60th quantile and by
finding the first point that deviates from the linear regression line
by more than 3 standard deviations of the estimated error. The
ratio of partial sums at this critical point was used to scale the read
density in one of the samples. The significance of the difference in
read counts was assessed by using the Skellam distribution as a null
model. We used 400 bp running windows to scan the genome. A
p-value cutoff of 10
27 was used to call significant windows, because
this cutoff roughly corresponds to an adjusted p-value of 0.05
based on the method of Poisson clumping heuristic for
approximating the probability of locally correlated rare events.
The relation between the Skellam and adjusted p-values is given by
pSkellam=2log(12padjusted) E[C]/L, where L is the genome size,
and E[C] the expected correlation length of Skellam p-values
across adjacent windows. Overlapping significant windows were
concatenated, and we report the new p-values recomputed in the
joined windows. More detailed descriptions are included in Text
S1.
Gene density analysis
The MM9 mouse genome was partitioned into disjoint 1 Mbp
bins. The log fold-change of normalized counts in paired ChIP-seq
data with Pcl3 knockdown or scramble was computed in each bin.
Gene density was computed by counting the number of RefSeq
genes in each 1 Mbp bin. Pearson correlation was computed
between gene density and log fold-change across bins. In
Figure 4B, we grouped the bins into units of 10; e.g., 10 denotes
bins with gene density greater than or equal 0 and less than 10.
Suz12 binding sites in miRNA promoters
To find miRNAs targeted by Suz12, we used a prior annotation
of miRNA promoters [64]. The differential Suz12 binding levels
shown in Figure 4D–4E were computed within Suz12 ChIP-seq
peaks overlapping with the annotated promoters.
Motif analysis
We used a greedy algorithm called LeitMotif which models the
background nucleotide distribution with the 9
th order Markov
dependence [86]. Motif lengths ranging between 6 and 15 were
used for scanning. Top scoring motifs with length 10 and 14 were
chosen for further analysis, because other motifs were either
contained in or contained those two motifs. Sequences obtained
from LeitMotif were aligned to produce the logos in Figure 9A and
to generate the PSSM matrices used in Figure 9B–9D. A custom C
code was used to scan the Suz12 sites with those PSSM matrices,
assuming independent bases in the background. Support vector
machine implemented in the e1071 R-package was used to classify
the Suz12 binding sites with 10-fold cross validation.
Accession number
The ChIP-seq data are available from Gene Expression
Omnibus under access number GSE28325.
Supporting Information
Figure S1 Suz12-TAP and Pcl3-V5 localize to the nucleus. (A)
Schematic of recombination events performed to create
Suz12
Suz12TAP/+. The wild type endogenous allele is not pictured.
Not to scale. (B) Staining of Suz12
Suz12TAP/+ with anti-FlagM2
(red), which overlays with nuclei stained with DAPI (blue). Scale
bar 10 mm. (C) Suz12 expression levels in wild type, Suz12
Gt/+,
Suz12
Rev/+, and Suz12
Suz12TAP/+ cell lines measured by qRT-PCR.
Error bars indicate standard deviation. Asterisk denotes statistical
significance of p,0.0001. Graph represents average expression of
three different clones in three experiments assayed in quadruplet.
(D) Wild type cells transfected with Pcl3-V5 and stained with anti-
V5 (red). V5 staining overlays with nuclei stained with DAPI
(blue). Scale bar 10 mm. Stainings were performed two times.
(TIF)
Figure S2 Depletion of Pcl3 does not affect ESC differentiation
to all three germ layers. (A) Protein levels of Pcl3 in scramble and
Pcl3 shRNA clones assessed by immunoblot of lysates immuno-
precipitated and probed with anti-Pcl3. For a positive control,
Pcl3-TAP was immunoprecipitated and probed for FlagM2. Each
lane represents a different clone. (B) Immunofluorescent staining
of scramble and Pcl3-shRNA treated ESCs with Oct4, and Nanog.
DAPI marks nuclei. Taken at 206. (C) Scramble and Pcl3 shRNA
ESCs stained for alkaline phosphatase activity. View of one well of
a 6-well plate and magnified at 166. (D) Pcl3 mRNA levels as
measured by qRT-PCR in wild type and Pcl3 overexpressing cells.
(E) Detection of Pcl3-TAP in wild type cells expressing Pcl3-TAP
by immunoprecipitating and probing with anti-FlagM2. (F)
Images of colonies stained with methylene blue formed from
scramble and Pcl3 shRNA cells. Experiment was performed five
times with two clones each of scramble and Pcl3 shRNA ESCs. (G)
Pcl3 expression in scramble and Pcl3-shRNA derived teratomas.
Representative of eight teratomas. (H) Teratomas expressing
scramble and Pcl3 shRNA stained for the neural marker NeuN
(green) and the neuron marker Tuj1 (red); muscle marker Actin
(green); basal layer skin marker K14 (green). All images contain
nuclear staining with DAPI (blue). Scale bar 20 mm. (I) Expression
levels of Nestin, T-brachyury (T-bra), Hnf4, and Pcl3 which represent
neuroectoderm, mesoderm, endoderm, and knockdown respec-
upon Pcl3 knockdown overlapping with Pcl2 and Pcl3 and (C) Suz12 binding sites unaffected upon Pcl3 knockdown and that do not overlap with Pcl2
and Pcl3. (D) Shown are the decision boundaries of a support vector machine classifier using these three features, where the purple regions
correspond to Suz12 co-localizing with Pcl2 and Pcl3. The predictor had a cross validation accuracy of 75%. (E) A model of Pcl3 and Pcl2 regulation of
PRC2 binding and activity. In wild type ESCs, Pcl3 promotes PRC2 binding and H3K27me3. Pcl2 antagonizes Pcl3-mediated Suz12 binding at sites
bound by both but promotes PRC2 function at sites solely regulated by Pcl2. Knockdown of Pcl3 causes decreased PRC2 binding and H3K27me3. Pcl2
does not compensate at Pcl2 and Pcl3 targets and continues to inhibit or promote PRC2 function depending on the gene.
doi:10.1371/journal.pgen.1002576.g009
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was performed with 3–6 clones. All immunoblots were performed
2–4 times, and a-tubulin was used as a loading control. All
stainings were performed 2–3 times in 2–4 clones or teratoma
samples. Expression analysis represents 3–4 experiments assayed
in quadruplicate. Error bars indicate standard deviation and
asterisks indicate statistical significance of p,0.005.
(TIF)
Figure S3 Depletion of Suz12 and Pcl3. (A) Quantification of
H3K27me3 depletion in Pcl3 shRNA treated cells. Graph shows an
approximate 80% decrease in H3K27me3 levels and represents ten
experiments using 2–6 clones each. (B) qRT-PCR and (C)
immunoblot indicating levels of Suz12 in cells treated with
increasing amounts of Suz12 siRNA 48 hrs and 72 hrs post-
transfection. b-actin was used as a loading control. (D) Transfection
with Suz12 and Pcl3 siRNAs causes decreased expression of Suz12
and Pcl3 respectively as measured by qRT-PCR. (E) Pcl3-TAP
localizes to the nucleus as assessed by immunofluorescent overlay of
FlagM2 (green) and DAPI (blue). E-cadherin (red) marks the cell
membrane. Scale bar 10 mm. Expression analysis was performed 2–
4 times and assayed in quadruplet. Error bars indicate standard
deviation, and asterisks indicate statistical significance of p,0.005.
Staining was performed twice with three different clones.
(TIF)
Figure S4 Pcl3 knockdown causes the most significant depletion
of Suz12 and H3K27me3 on chromosome 11. (A) Number of
sequenced and aligned reads for ChIP-sequencing. (B) Partial sums
of order statistics of binned read counts in the scramble and Pcl3
shRNA cells were computed, and their ratios are plotted for the
Suz12FlagM2ChIPand H3K27me3ChIP.Thetheoreticalratioof
partial sums is almost linear when two samples are identically
distributed, as shown by the red line. The blue vertical bar marks
the quantile at which the ratio begins to deviate from linearity, and
it effectively separates the background bins from ChIP-enriched
bins. The ratio at this quantile was used to scale the Pcl3 ChIP-seq
counts. (C) Boxplot comparing Suz12 binding sites to Marson et al.
[64]. The most significant Suz12 binding sites identified in our
dataset overlap with Marson et al. while the less significant binding
sites make up the majority of the remaining sites not identified in
Marson et al. ChIP score=2log p-value for Suz12 ChIP-seq/
Input. (D) Graph of 2log p-values indicates that the mostsignificant
Suz12 ChIP-seq binding sites are more likely to decrease following
Pcl3 knockdown, while sites unaffected by Pcl3 knockdown are most
oftenlesssignificantSuz12 ChIP-seqbindingsites.(E)Boxplotoflog
fold-changes in ChIP-seq read density within Suz12 binding sites.
Suz12 binding and H3K27me3 in Pcl3 knockdown ESCs were
decreased on all chromosomes. Chromosome 11 was the most
significantly depleted (Pair-wise Wilcoxon rank sum test p-
value,1.3610
215 for Suz12 binding sites; p-value,5.2610
214
for H3K27me3). (F) Sites with decreased Suz12 binding upon Pcl3
knockdown tend to be devoid of E2f1 [63] (Fisher test p-
value=9.5610
253). (G) Suz12 ChIP-qRT-PCR indicating that at
some sites Pcl3 depletion does not affect Suz12 binding. (H) ChIP-
qRT-PCR for H3K4me3 in scramble and Pcl3 shRNA ESCs. Error
bars indicate standard deviation, and asterisks indicate statistical
significance of p,0.04. ChIP-qRT-PCRs was performed 2–3 times
and assayed in quadruplicate.
(TIF)
Figure S5 Pcl3 co-localizes with Suz12. (A) Aligning Suz12 and
Pcl3 ChIP-seq reads at Pcl3 peak centers shows genome-wide co-
localization of Pcl3 with Suz12. (B) To estimate the percentage
overlap between Suz12 and Pcl3 binding sites, a sensitivity analysis
was performed by varying the Skellam distribution p-value cutoff
for calling peaks, ranging between 10
27 to 10
212. The boxplot
shows the percentage of Pcl3 peaks at each p-value cutoff found to
be overlapping with Suz12 binding sites that pass the p-value
cutoffs 10
27,1 0
28,1 0
29,1 0
210,1 0
211, and 10
212.
(TIF)
Figure S6 Pcl3 misregulates a subset of genes. (A, C) Relative
expression of genes that either increased or decreased upon Pcl3
knockdown as measured by qRT-PCR and microarray. Cells were
collected following selection for Pcl3 depletion, approximately 3–4
weeks. Microarray and qRT-PCR were performed with 2–6
clones each for control and Pcl3 knockdown ESCs. qRT-PCR
analysis represents 2–3 different experiments performed with
multiple clones and assayed in quadruplicate. For both graphs,
error bars indicate standard deviation and data represents
statistical significance of p,0.05. (A) Graph represents expression
levels in ESCs that have not been pre-plated to remove
differentiated cells. (B) Genes that show depleted Suz12 binding
following Pcl3 knockdown and that are misregulated by micro-
array analysis. Cells in (C) were pre-plated to remove differenti-
ated cells and then expression was assessed. (D) Binding profile of
Suz12 and Pcl3 at the Suz12 locus. Turquoise puncta are
background and not statistically significant.
(TIF)
Table S1 Gene expression changes upon Pcl3 knockdown by
microarray. Microarray data indicating fold changes in gene
expression in ESCs expressing Pcl3 shRNA as compared to
scramble shRNA ESCs. Comparison included six control samples
and six Pcl3 shRNA clones.
(XLS)
Table S2 Gene expression changes in pre-plated Pcl3 shRNA
ESCs by microarray. Microarray data indicating fold changes in
gene expression in pre-plated ESCs expressing Pcl3 shRNA as
compared to scramble shRNA ESCs. Comparison included two
scramble clones and two Pcl3 shRNA clones.
(XLS)
Text S1 Supplemental methods. Detailed description of the
microarray and ChIP-sequencing methods as well as a list of the
antibodies and primers used.
(DOC)
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